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Pancreatitis is a complex, progressively destructive inflammatory disorder. Alcohol was long
thought to be the primary causative agent, but genetic contributions have been of interest since the
discovery that rare PRSS1, CFTR, and SPINK1 variants were associated with pancreatitis risk.
We now report two significant genome-wide associations identified and replicated at PRSS1-
PRSS2 (1×10-12) and x-linked CLDN2 (p < 1×10-21) through a two-stage genome-wide study
(Stage 1, 676 cases and 4507 controls; Stage 2, 910 cases and 4170 controls). The PRSS1 variant
affects susceptibility by altering expression of the primary trypsinogen gene. The CLDN2 risk
allele is associated with atypical localization of claudin-2 in pancreatic acinar cells. The
homozygous (or hemizygous male) CLDN2 genotype confers the greatest risk, and its alleles
interact with alcohol consumption to amplify risk. These results could partially explain the high
frequency of alcohol-related pancreatitis in men – male hemizygous frequency is 0.26, female
homozygote is 0.07.
The exocrine pancreas is a simple digestive gland of only two primary cell types, each with
a single function (Supplementary Figure 1). Recurrent acute pancreatic inflammation can,
but does not always, progress to irreversible damage of the gland, including fibrosis,
atrophy, pain, and exocrine and endocrine insufficiency,1-3 known as chronic pancreatitis
Different genetic and environmental factors produce the same clinical phenotype4.
We collected biological samples and phenotypic data from 1000 patients with recurrent
acute pancreatitis and chronic pancreatitis plus controls in the North American Pancreatitis
Study 2 (NAPS2)5. The primary environmental risk factor identified was heavy alcohol
drinking when symptoms of pancreatitis began, based on the assessment of the study
physician, called here alcohol-related pancreatitis.
To further define genetic risk, we conducted a two-stage (discovery/replication)
genomewide association study (GWAS). The final data set for the Stage 1 cohort included
676 chronic pancreatitis cases and 4507controls of European ancestry (Supplementary Figs.
2-3) genotyped at 625,739 SNPs (Table 1; Supplementary Table 1). Genomewide significant
associations (p-value < 5 × 10-8) were identified at two loci. The most highly associated
SNP fell in Xq23.3, dubbed the CLDN2 locus, the other in 7q34, the PRSS1-PRSS2 locus
(Fig. 1; Table 2; Supplementary Figs. 4-5, Supplementary Table 2). CLDN2 encodes the
protein claudin-2, while PRSS1 encodes cationic trypsinogen, and PRSS2 encodes anionic
trypsinogen.
The Stage 2 cohort included 910 cases (331 chronic pancreatitis, 579 recurrent acute
pancreatitis; Table 1, Supplementary Table 1), again genotyped at 625,739 SNPs, and 4170
controls, most genotyped previously on the Illumina 1M. All subjects were of European
ancestry as determined by genetic analyses. Recurrent acute pancreatitis and chronic
pancreatitis were modeled as having common susceptibilities, with chronic pancreatitis
occurring over time in the presence of additional disease-modifying factors.6 It is possible
that this assumption reduces power relative to a study comprising solely chronic pancreatitis
or recurrent acute pancreatitis cases. Our primary targets in Stage 2 were the PRSS1-PRSS2
and CLDN2 loci, although we also conducted a joint analysis7 of Stage 1 and Stage 2 data to
uncover any new risk loci. After controlling for ancestry, these data demonstrated significant
effects for the CLDN2 and PRSS1-PRSS2 loci (Figure 1; Supplementary Table 2-3;
Supplementary Figs. 6-7). Quality of SNP genotypes supported the association
(Supplementary Fig. 8). The frequencies of the putative risk alleles at these 2 loci were 0.57
for the C allele at rs10273639 (PRSS1-PRSS2 locus), with the minor T allele reducing risk,
and 0.26 for the T allele at rs12688220 (CLDN2 locus). No other locus shows association
after accounting for SNP genotype quality (Supplementary Figs. 6-8).
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tPRSS1 gain-of-function mutations, such as p.R122H, increase risk for recurrent acute
pancreatitis and chronic pancreatitis8, as do increased copy number9,10. Rare loss-of-
function mutations in PRSS2 are protective11. However, rs10273639 is in the 5′ promoter
region of PRSS1. Because it is the only highly associated SNP in the locus, we validated its
genotypes by independent TaqMan genotyping and also genotyped two SNPs in linkage
disequilibrium with it (footnote, Supplementary Table 4)1213. We screened PRSS1 for rare
variants in 1138 subjects: 418 chronic pancreatitis, 350 recurrent acute pancreatitis, and 379
controls. Three known disease-associated variants (A16V, N29I, R122H) were identified in
23 subjects (Supplementary Table 4). These gain-of-function variants occur almost solely in
cases (22 out of 23), and two of them, A16V and R122H, likely fall on the C or risk
haplotype of this locus (Supplementary Table 4). Nonetheless, with only 19 A16V and
R122H events in cases, these rare alleles cannot account for the association observed at this
locus.
Sixty-nine control pancreas tissue samples from three sources were genotyped at
rs10273639, and cDNA was used to quantify PRSS1 and control gene expression
(Supplementary Table 5). For all three sets of quantitative PCR data, the slope relating count
of genotype C allele to PRSS1 expression level was positive; together, the samples provide
evidence (p = 0.01) that alleles at rs10273639 affect expression of PRSS1: expression levels
were highest in patients with two C alleles at rs10273639, intermediate in heterozygotes, and
lowest in subjects with two T alleles. Based on this evidence, we posit that reduced
trypsinogen production protects the pancreas from injury, as has been observed in genetic
mouse models14.
CLDN2 is considered the primary candidate gene within our CLDN2 locus. Claudin-2 is
attractive because it serves as a highly regulated tight junction protein forming low-
resistance, cation-selective ion and water channels between endothelial cells15,16 and is
normally expressed at low levels between cells of the pancreatic ducts and in pancreatic
islets17,18. The CLDN2 promoter includes an NFκB binding site19, and gene expression is
enhanced in other cells under conditions associated with injury or stress20-22. Claudin-2 can
also be expressed by acinar cells when stressed, as reported in porcine models of acute
pancreatitis23. Other genes within the CLND2 locus include MORC4, RIPPLY1, and
TBC1D8B. MORC4 is expressed at low levels in most tissues, including the pancreas, with
higher levels in the placenta and testis24. The MORC4 protein contains a CW four-cysteine
zinc-finger motif, nuclear localization signal, and nuclear matrix-binding domain,
suggesting that it may be a transcription factor24, but its expression does not appear to
correlate with pancreatitis (Supplementary Fig. 9). RIPPLY1 and TBC1D8B are not known
to be expressed in the pancreas.
To our knowledge, genetic variations in CLDN2 have never been associated with disease in
humans. We assessed DNA sequence variants around CLDN2, RNA, and protein expression
for claudin-2 in control tissue classified by histology and genotype (Supplementary Table 6,
Supplementary Fig. 10). Evaluating 1000 Genomes data, no exonic variation was identified
that could explain the association signal. Using materials and methods described previously
for PRSS1 expression, CLDN2 expression levels in control tissues did not correlate with the
CLDN2 locus risk genotype (p-value = 0.32). Protein was extracted from the tissue, and
only one protein band of the appropriate size was observed with anti-claudin-2 antibodies on
Western blot, which correlated with tissue inflammation as determined by systematic
grading of histology in adjacent tissue (Fig. 2A, Supplementary Fig. 10).
Immunohistochemical staining with anti-claudin-2 antibodies was verified in normal tissue
(Fig. 2B), with kidney, duodenum, and bile ducts serving as additional positive controls (not
shown). Protein localization was assessed in 12 GWAS cases who underwent pancreatic
surgery: 6 with the CLDN2-containing high-risk genotype and 6 without. Claudin-2
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tcytoplasmic granular staining was markedly increased in both duct and acinar cells in
chronic pancreatitis cases (Fig. 2C-E). Only chronic pancreatitis cases with the high-risk
CLDN2 genotype demonstrated moderate-to-strong claudin-2 staining along the basolateral
membrane of acinar cells (Fig. 2D, 2E, Supplementary Table 6). Claudin-2 was also
expressed in macrophages, which could contribute to the pathologic inflammatory process25
(Fig. 2C, F).
Most studies report excessive alcohol consumption as the major risk factor for adult-onset
chronic pancreatitis26-29. However, only 3% of patients who are alcoholics develop chronic
pancreatitis30, suggesting a pancreas-targeting risk factor. We compared genotypes based on
whether pancreatitis was alcohol-related (yes/no) 5,31. Setting control genotypes counts as
the baseline category to be compared with case genotypes, the jointly estimated odds ratios
for cases with a positive alcohol-related pancreatitis was greater for both rs10273639
(PRSS1-PRSS2 locus) and rs12688220 (CLDN2 locus) than those estimated for cases with a
negative alcohol-related pancreatitis (Table 3). Thus, the effects of both loci appeared to be
amplified by alcohol consumption. In a case-only analysis, both loci appear to interact with
alcohol-related pancreatitis (Table 3), the CLDN2 locus most prominently (p-value =
4×10-7).
We conclude that a common allele in the PRSS1-PRSS2 locus is associated with lower
PRSS1 gene expression and that this effect is independent of the previously reported rare
gain-of-function PRSS1 variants that increase susceptibility to both recurrent acute
pancreatitis and chronic pancreatitis8. For this reason, and because risk variants at the
PRSS1-PRSS2 locus exert a similar effect in patients with recurrent acute pancreatitis or
chronic pancreatitis, it is reasonable to conjecture that variation at rs10273639 or variation
in linkage disequilibrium with it directly affects risk for chronic pancreatitis and recurrent
acute pancreatitis through its impact on trypsinogen expression. Variation at the CLDN2
locus, however, is much more strongly associated with chronic pancreatitis than recurrent
acute pancreatitis, suggesting that it likely acts as a disease modifier to accelerate transition
from recurrent acute pancreatitis to chronic pancreatitis. The significant association of the
CLDN2 locus with alcohol suggests that the high-risk allele in the CLDN2 locus may
modify risk through a non-trypsin-dependent process. Thus, we have characterized two
common genetic risk modifiers for sporadic and alcohol-related chronic pancreatitis.
Online Methods
Subject recruitment
Details of recruitment of cases and controls are reported in Supplementary Table 1. All
studies were conducted under institutional review board-approved protocols.
Stage 1 samples
All N = 758 Stage 1 case samples were from the North American Acute Pancreatitis Study
(NAPS2 5) were diagnosed with chronic pancreatitis, and were characterized for alcohol-
related pancreatitis (Table 1). chronic pancreatitis occurs in less than 0.05% of the
population, so a convenience sample provides essentially identical power as a same-sized
sample of controls selected for the absence of chronic pancreatitis 32. For controls, we used
genotypes from 4076 cases and controls from the Alzheimer Disease Genetics Consortium
(ADGC) and 493 NAPS2 subjects, all genotyped on the same platform as the chronic
pancreatitis samples.
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tStage 2 samples
The Stage 2 samples consisted of N=343 chronic pancreatitis and N=627 recurrent acute
pancreatitis cases (Table 1, Supplementary Table 1) as well as 4191 control subjects (3986
from the NeuroGenetics Research Consortium, NGRC, and 205 NAPS2 controls).
Genotypes
All cases and NAPS2 controls were genotyped by the University of Pittsburgh Genomics
and Proteomics Core Laboratories using the Illumina HumanOmniExpress Beadchip.
Samples were processed and scanned using the manufacturer's recommended protocols with
no modifications. ADGC samples33 were also genotyped using Illumina
HumanOmniExpress Beadchips, whereas NGRC samples 34 were genotyped on the Illumina
Human1M-Duo DNA Analysis BeadChip.
Quality Control (QC) for Stage 1
QC was performed for individuals and then SNPs to determine which samples and SNPs
should not be included in the analysis (“dropped’). Assessing sex miscalls based on ×
chromosome genotypes using Plink35, 7 chronic pancreatitis cases and 20 controls (10
NAPS2; 10 ADGC) were dropped. Based on the requirement for ≥ 95% complete genotypes
per individual, 40 cases and 27 controls (20 NAPS2 controls and 7 ADGC controls) were
dropped. Searching duplicate or highly related samples based on genotype and using GCTA
software 36 (Genetic Relationship Matrix score GRM > 0.4), 35 cases and 78 controls (2
NAPS2, 76 ADGC) were dropped. After these QC filters, 676 cases and 4507 controls
remained for association analysis.
SNP QC was first performed using NAPS2 and ADGC samples separately.. Ancestry was
estimated using dacGem37 based on 9700 SNPs that had a genotype completion rate of
≥99.9%, a minor allele frequency MAF ≥ 0.05, and were separated by at least 500Kb.
Analysis of genotypes from NAPS2 subjects identified 1 significant dimensions of ancestry
and clustered subjects into 3 groups (Supplementary Fig. 1). Groups A and B, illustrated in
Supplementary Figure 1, delineate 764 and 282 subjects, respectively, of European ancestry
(self-identified); SNP QC for MAF and Hardy Weinberg Equilibrium (HWE) were
performed on data from these subjects. Of 731,442 SNPs received, 633,790 passed QC
filters. SNPs were dropped for the following reasons: 3165 for map location; 11,977 for call
rate; 77,300 for MAF < 0.01; and 5219 failed HWE (p-value < 0.005).
ADGC data were received in three waves of 1763, 1110, and 1266 subjects. In the first
wave, 659,224 SNPs were received, while in waves two and three, 730,525 SNPs were
received. After QC as described for the chronic pancreatitis cohort, including harmonization
with SNPs passing QC in the chronic pancreatitis cohort, 604,059, 632,761, and 633,023
SNPs remained, respectively. After merging cohorts, 30 related subjects were dropped,
leaving 4046 ADGC subjects. Of the 633,615 unique SNPs in this ADGC, QC filters
dropped 5 for low MAF and 5316 for HWE, leaving 628,294 SNPs. Combining ADGC and
chronic pancreatitis cohorts and performing another round of QC yielded 625,739 SNPs for
analysis.
QC for Stage 2
QC for individuals was performed as described for Stage 1. These individual-specific QC
filters removed 60 cases, leaving 331 chronic pancreatitis and 579 recurrent acute
pancreatitis cases for analysis; 14 controls were also removed, leaving 4177 controls for
analysis. We analyzed all SNPs passing QC at Stage 1.
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To control confounding due to ancestry, the first 10 major eigenvectors from the spectral
decomposition were used as covariates in Stage 1 and Stage 2 analyses38, although only one
was significant. We contrasted the genotypes of case subjects and controls via logistic
regression and a log-additive (logit) model using Plink35. Genotypes for any SNPs showing
association p-value < 5 × 10-7 were manually inspected for valid genotype clustering. SNPs
showing poor-quality clustering were excluded. Following Skol et al. 7 and others, we take
an overall significance level of 5 × 10-8 and 5 × 10-7 for strongly suggestive association.
To determine whether alcohol interacts with genetic variation to alter risk of pancreatitis,
data from cases were fit to a general linear model in which count of alleles or genotypes
predicted alcohol etiology (yes/no). The test statistic was obtained as a likelihood ratio chi-
square. Note that in these analyses and any analyses other than genomewide association, we
model the male genotypes as 0 and 2 39,40. For the genomewide association, Plink encodes
the count of minor alleles in males as 0 and 1 and includes a sex effect, but the 0/2 encoding
for males is a more powerful approach39,40 .
DNA extraction
DNA was obtained using standard methods41.
Pancreatic tissue processing
Tissue was obtained from two sources [Pitt and Pancreatic Adenocarcinoma Gene-
Environment Risk (PAGER) from the University of Pittsburgh and PSU from Pennsylvania
State University] and processed in three batches: banked (Pitt) and prospectively collected
(PAGER) surgical waste from uninvolved pancreas and normal pancreas specimens from the
Gift of Life Program that were not used for transplantation (PSU). PAGER samples were
snap-frozen, placed in RNAlater solution (Ambion), and stored at –80°C. PSU pancreas
samples were also snap frozen and preserved in formalin or placed in RNAlater solution.
RNA was isolated using Trizol reagent (Invitrogen), and its quality examined in 1% agarose
gel stained with ethidium bromide. cDNA was transcribed using oligo dt primers and the
Superscript II reverse transcriptase kit (Invitrogen).
Gene Expression
Relative expression of PRSS1, PRSS2, CTRC, and 18S was determined by analyzing cDNA
using Taqman®-based rtPCR assays (Applied Biosystems). Raw absolute quantitation
results were analyzed and converted to relative expression results by software packages SDS
V2.3 and DataAssist V1.0 (Applied Biosystems). Assays were repeated in triplicate or
quadruplicate. Three sets of samples were assessed, two from Pitt (N=10 and 22) and one
from PSU (N=37). PSU results were normalized against 18S, Pitt against CTRC. From each
of these three data sets, mean gene expression per sample was regressed against allele count
to obtain an estimated slope, standard error, and z-score. We then calculated an overall z-
score as a weighted average of the individual z-scores, with weights determined by sample
size.
Antibodies
Antibodies against claudin proteins (Invitrogen) were assessed using Western blot for mouse
anti-claudin-2 (Catalog No. 32-5600), mouse anti-claudin-4 (Catalog No. 32-9400), and
mouse alpha-tubulin antibody (Catalog no. AA12.1 The Developmental Studies Hybridoma
Bank at the University of Iowa, http://dshb.biology.uiowa.edu/Antibody-list).
Immunohistochemistry was performed using monoclonal antibodies for claudin-2 (Catalog
#32-5600,1:1,000 dilution). Immunoflourescence was performed using mouse anti-claudin-2
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t(Catalog No. 32-5600) and goat anti-human CD68 (Catalog #sc-7082, Santa Cruz
Biotechnology Inc.). The secondary antibodies for Immunofluorescence were goat anti-
mouse CY3 and anti goat Cy5 from Jackson Immunoresearch.
SDS-PAGE and WESTERN Blotting
Protein homogenates for Western blotting were obtained from snap-frozen tissue that was
homogenized and sonicated in lysis buffer supplemented with protease inhibitors. Protein
concentration was determined by the Bradford method using a kit from Bio-Rad. Proteins
were separated on 12% SDS-PAGE42 followed by transfer to polyvinylidene difluoride
(PVDF) membranes43, for Western blotting44. Immunodetection of bound antibodies on
PVDF membrane was performed using ECL reagents (Amersham Biosciences). All
procedures were carried out according to manufacturer instructions.
Immunohistochemistry
Standard automated immunohistochemistry was performed for claudin 2 (antibodies listed
above) on formalin-fixed, paraffin-embedded, 5 micron-thick tissue sections. Following
deparaffinization in xylene and rehydration in ethanol, antigen retrieval was performed
using EDTA pH8 buffer. The Dako Autostainer Plus was used; the slides were incubated for
30 minutes with the primary antibodies, followed by incubation with the secondary reagent
(Mach 2 Mouse HRP Polymer from Biocare Medical) for 30 minutes. The chromogen was
developed (Dako DAB+) for 10 minutes. The immunohistochemical stains were reviewed
by one of the authors (A.M.K.). Cytoplasmic, granular, and membranous staining,
predominantly in the lateral cell membranes, were graded on an intensity scale of 0-4 (0,
negative; 1, weak; 2, moderate; 3, strong). The staining intensity was very patchy from
lobule to lobule in most cases.
Immunofluorescence
Cryostat sections (5 micron) of pancreas were washed 3 times with phosphate-buffered
saline (PBS), followed by 3 washes with solution of .5% BSA in PBS. Sections were
blocked with 2% BSA solution for 30 minutes. The slides were incubated for 1 hour at room
temperature with primary antibody for claudin-2 1:100 and goat anti-human CD68 in 0.5%
BSA solution. Slides were washed 3 times with BSA solution and incubated for 1 hour at
20°C with 1:500 dilution anti-goat CY5 and 1:1000 dilution goat anti-mouse CY3 secondary
antibodies in BSA solution. Nuclei were stained with Hoeschts dye (bisbenzamide 1mg/
100ml water) for 30 seconds. After 3 rinses with PBS, sections were cover slipped with
Gelvatol mounting media. Fluorescent images were captured with an Olympus Fluoview
1000 confocal microscope (software version 1.7a). The Cy5 signal (CD68) was
pseudocolored as green to show colocalization with the red Claudin signal as yellow.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Manhattan plot showing the negative log (base 10) of the p-value for the association of SNP
genotype with affection status for all SNPs passing quality control filters and falling within a
selected region of the PRSS1-PRSS2 and CLDN2 loci. Regions selected to highlight the
most associated SNPs. Squares indicate Stage 1 results, circles for Stage 2, diamonds for
combined Stage 1 and 2 data. After accounting for the most highly associated SNP at each
locus, no other SNP approached genomewide-significant association.
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Expression and localization of claudin-2 in the human pancreas using mouse anti-claudin-2
antibodies based on rs12688220 genotype. A. Western blot of anti-claudin-2 antibody from
3 control samples genotyped at rs12688220 (TT is high risk). The antibody reacts with a
protein at ~22-23 kDa, consistent with claudin-2. Samples had inflammation and/or fibrosis
on histology of adjacent tissue. α-tubulin, loading control. Blots from all controls are
presented in Supplementary Figure 8. B. Anti-claudin-2 staining (brown color) of normal-
appearing control tissue localizing to ducts but not to acinar cells (scale bar=50μm). C.
Severe chronic pancreatitis from a case with the high-risk (T male or TT female) genotype.
Claudin-2 staining localizes to the intralobular duct (Duct), atrophic acini (*), and cells with
morphologic appearance of macrophages (arrow)(scale bar=50μm). D. Chronic pancreatitis
tissue from a patient with the low-risk genotype (CC or CT) with staining localizing to the
duct and granular staining in acinar cells (scale bar = 100 μm). E. Chronic pancreatitis,
high-risk genotype with intense staining of acinar cell basolateral membrane (scale bar=100
μm, enlarged in inset, scale bar=10μm). F. Immunofluorescence staining of control human
pancreatic tissue claudin-2 staining (red) localizing to the ducts (*) and co-localizing with
the macrophage marker CD68 (green, colocalized with red is yellow, arrows. Nuclei stained
with Hoechst's dye, blue, scale bar = 100μm).
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Table 3
Allele frequencies for rs10273639 (risk allele C) and rs12688220 (risk allele T) when data are stratified by
controls or pancreatitis ± alcohol-related diagnosis.
Status Alcohol-related Number of individuals rs102736391 (C) frequency rs126882201 (T) frequency
Control -- 8029 0.576 0.261
Pancreatitis
No 1129 0.634 0.322
Yes 447 0.696 0.427
1
Using data from cases only and in a joint analysis of both SNPs, rs12688220 predicts alcohol-related pancreatitis as genotypes (χ2=29.57; DF=2;
p-value = 4×10-7) or count of risk alleles (χ2=13.17; DF=1; p-value = 3×10-4). rs10273639 (PRSS1-PRSS2 locus) is a significant predictor (count
of risk alleles: χ2=5.68; DF=1; p-value = 0.017; genotypes: χ2=6.05; DF=2; p-value = 0.049), even after accounting for the effects of rs12688220.
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